We believe the concurrent reduction in asparagine and glutamine levels under asparaginase treatment may be attributed to several interconnected mechanisms: 1) Metabolic compensation: As asparagine is depleted, tumor cells may undergo metabolic reprogramming to alleviate the impact of asparagine loss (46). This evidence concerns the gene ASPG and neoplasm.